Skip to main content

Drug Interactions between Axid and lasmiditan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nizatidine lasmiditan

Applies to: Axid (nizatidine) and lasmiditan

MONITOR: Coadministration of lasmiditan and agents that lower heart rate may increase the risk of bradycardia. In clinical trials, lasmiditan was associated with heart rate decreases of 5 to 10 beats per minute (bpm) while placebo was associated with decreases of 2 to 5 bpm. In a drug interaction study, a single 200 mg dose of lasmiditan led to an additional heart rate decrease of 5 bpm when given with propranolol.

MANAGEMENT: Caution is advised during coadministration of lasmiditan and agents that lower heart rate if the estimated decrease in heart rate may present a clinical risk. Consider monitoring heart rate in patients for whom the estimated decrease in heart rate may not be tolerated.

References

  1. (2019) "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer